Precision BioSciences (Precision BioSciences) Interest Expense : $-2.23 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Precision BioSciences's interest expense for the three months ended in Dec. 2023 was $ -0.58 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.23 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Precision BioSciences's Operating Income for the three months ended in Dec. 2023 was $ -14.89 Mil. Precision BioSciences's Interest Expense for the three months ended in Dec. 2023 was $ -0.58 Mil. Precision BioSciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Precision BioSciences Interest Expense Historical Data

The historical data trend for Precision BioSciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Interest Expense Chart

Precision BioSciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.18

-0.13

-1.11

-2.23

Precision BioSciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.49	-0.52	-0.55	-0.58	-0.58

Precision BioSciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.23 Mil.

Precision BioSciences (NAS:DTIL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Precision BioSciences's Interest Expense for the three months ended in Dec. 2023 was $-0.58 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-14.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $7.72 Mil.

Precision BioSciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Precision BioSciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Precision BioSciences (Precision BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

PBS:Germany

Address

302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701

Website

https://www.precisionbiosciences.com

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Executives

J. Jefferson Smith	10 percent owner	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List	officer: Chief Medical Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso	director, officer: President and CEO	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca	officer: General Counsel	C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly	officer: Interim CFO	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis	10 percent owner	LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz	director, 10 percent owner, officer: Chief Scientific Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown	director	10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire	director	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson	officer: Chief Development Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel	director	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane	director, 10 percent owner, officer: President and CEO	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton	officer: VP & Corporate Controller	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701